Disease-Free Survival [přežití bez známek nemoci]

topical
1 454
Terms

přežití po terapii bez příznaků nemoci

 

Survival, Disease-Free

Persistent link   https://www.medvik.cz/link/D018572
Definition

Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.

Annotation
usually NIM; coordinate with specific disease /ther or more specific qualifier
obvykle NIM; kombinuj s konkrétní nemocí s podheslem /terapie nebo přesnějšími kvalifikátory
DUI
D018572 MeSH Browser
CUI
M0027839
Previous indexing
Prognosis (1980-1994)
History note
95
Public note
95

E Analytical, Diagnostic and Therapeutic Techniques and Equipment
E01 Diagnosis 1 794
E01.789 Prognosis 9 806
E01.789.800 Treatment Outcome 22 068
E01.789.800.190 Disease-Free Survival 1 454
E01.789.800.238 Early Termination of Clinical Trials 17
E01.789.800.262 Pathologic Complete Response 8
E01.789.800.285 Progression-Free Survival 553
E01.789.800.379 Response Evaluation Criteria in Solid Tumors 44
E01.789.800.570 Sustained Virologic Response 20
E01.789.800.665 Therapeutic Index 6
E01.789.800.713 Treatment Expectations
E01.789.800.760 Treatment Failure 689
E05 Investigative Techniques 210
E05.318 Epidemiologic Methods 1 033
E05.318.740 Statistics as Topic 13 127
E05.318.740.998 Survival Analysis 3 098
E05.318.740.998.300 Disease-Free Survival 1 454
E05.318.740.998.650 Kaplan-Meier Estimate 741
E05.318.740.998.738 Progression-Free Survival 553
E05.318.740.998.825 Proportional Hazards Models 481

N Health Care
N04 Health Services Administration 1 758
N04.761 Quality of Health Care 2 515
N04.761.559 Outcome and Process Assessment, Health Care 1 870
N04.761.559.590 Outcome Assessment, Health Care 590
N04.761.559.590.800 Treatment Outcome 22 068
N04.761.559.590.800.190 Disease-Free Survival 1 454
N04.761.559.590.800.379 Early Termination of Clinical Trials 17
N04.761.559.590.800.427 Pathologic Complete Response 8
N04.761.559.590.800.474 Progression-Free Survival 553
N04.761.559.590.800.569 Response Evaluation Criteria in Solid Tumors 44
N04.761.559.590.800.665 Sustained Virologic Response 20
N04.761.559.590.800.713 Therapeutic Index 6
N04.761.559.590.800.737 Treatment Expectations
N04.761.559.590.800.760 Treatment Failure 689
N05 Health Care Quality, Access, and Evaluation 690
N05.715 Quality of Health Care 2 515
N05.715.360 Health Care Evaluation Mechanisms 202
N05.715.360.575 Outcome and Process Assessment, Health Care 1 870
N05.715.360.575.575 Outcome Assessment, Health Care 590
N05.715.360.575.575.800 Treatment Outcome 22 068
N05.715.360.575.575.800.190 Disease-Free Survival 1 454
N05.715.360.575.575.800.379 Early Termination of Clinical Trials 17
N05.715.360.575.575.800.427 Pathologic Complete Response 8
N05.715.360.575.575.800.474 Progression-Free Survival 553
N05.715.360.575.575.800.569 Response Evaluation Criteria in Solid Tumors 44
N05.715.360.575.575.800.665 Sustained Virologic Response 20
N05.715.360.575.575.800.713 Therapeutic Index 6
N05.715.360.575.575.800.737 Treatment Effect Heterogeneity 1
N05.715.360.575.575.800.749 Treatment Expectations
N05.715.360.575.575.800.760 Treatment Failure 689
N05.715.360.750 Statistics as Topic 13 127
N05.715.360.750.795 Survival Analysis 3 098
N05.715.360.750.795.300 Disease-Free Survival 1 454
N05.715.360.750.795.650 Kaplan-Meier Estimate 741
N05.715.360.750.795.738 Progression-Free Survival 553
N05.715.360.750.795.825 Proportional Hazards Models 481
N06 Environment and Public Health 203
N06.850 Public Health 4 060
N06.850.520 Epidemiologic Methods 1 033
N06.850.520.830 Statistics as Topic 13 127
N06.850.520.830.998 Survival Analysis 3 098
N06.850.520.830.998.300 Disease-Free Survival 1 454
N06.850.520.830.998.650 Kaplan-Meier Estimate 741
N06.850.520.830.998.825 Progression-Free Survival 553
N06.850.520.830.998.912 Proportional Hazards Models 481

Add